Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556194 | 0.81 | CYP1A2 (0.52) | KMT2AMEN1SLC40A1CYP1A2TDP1 | |
| SCHEMBL4810431 | 0.81 | CYP1A2 (0.52) | KMT2AMEN1SLC40A1CYP1A2TDP1 | |
| SCHEMBL13219481 | 0.81 | CYP1A2 (0.52) | KMT2AMEN1SLC40A1CYP1A2TDP1 | |
| SCHEMBL29828916 | 0.81 | CYP1A2 (0.52) | KMT2AMEN1SLC40A1CYP1A2TDP1 | |
| SCHEMBL454942 | 0.79 | CYP1A2 (0.55) | KMT2AMEN1SLC40A1CYP1A2TDP1 | |
| SCHEMBL5773989 | 0.79 | CYP1A2 (0.51) | KMT2AMEN1SLC40A1CYP1A2TDP1 | |
| SCHEMBL6573464 | 0.79 | KDM4E (0.65) | KMT2AMEN1SLC40A1CYP1A2TDP1 | |
| Bromide SCHEMBL1143538 | 0.78 | CYP1A2 (0.53) | KMT2AMEN1SLC40A1CYP1A2TDP1 | |
| SCHEMBL15661629 | 0.78 | CYP1A2 (0.50) | KMT2AMEN1SLC40A1CYP1A2TDP1 | |
| SCHEMBL13437127 | 0.78 | CYP1A2 (0.50) | KMT2AMEN1SLC40A1CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070712-A1 | Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-11 | — | — | US | disclosed |
| EP-3283463-B1 | DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY | UNIV PENNSYLVANIA (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10774047-B2 | Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-09-15 | — | — | US | disclosed |
| US-20180111904-A1 | DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2018-04-26 | — | — | US | disclosed |
| EP-3283463-A1 | DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY | The Trustees Of The University Of Pennsylvania (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168721-A1 | DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-10-20 | — | — | WO | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-2029577-A2 | CRYSTALLINE FORMS OF 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE | Wyeth (US) | 2009-03-04 | — | — | EP | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| WO-2006135839-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | WYETH (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1641785-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS | Wyeth (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | WYETH | 2005-03-17 | — | — | US | disclosed |
| WO-2004099191-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774047-B2 | Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy | ATG7, BECN1, SQSTM1 | KMT2A 1608/4885MEN1 3124/4885SLC40A1 3011/4885 |
| US-20210070712-A1 | Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy | ATG7, BECN1, SQSTM1 | KMT2A 1608/4885MEN1 3124/4885SLC40A1 3011/4885 |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | HTR5A, HTR2C, HTR1D | KMT2A 1021/4885MEN1 2303/4885SLC40A1 3573/4885 |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | TPH1, TPH2, HTR2C | KMT2A 1907/4885MEN1 3795/4885SLC40A1 3412/4885 |
| US-20180111904-A1 | DIMERIC QUINACRINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR CANCER THERAPY | ATG7, BECN1, SQSTM1 | KMT2A 1608/4885MEN1 3124/4885SLC40A1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.